Association of statin therapy with clinical outcomes in patients with vasospastic angina: Data from Korean health insurance review and assessment service

So Jin Park, Hyejeong Park, Danbee Kang, Taek Kyu Park, Jinkyeong Park, Joongbum Cho, Chi Ryang Chung, Kyeongman Jeon, Eliseo Guallar, Juhee Cho, Gee Young Suh, Jeong Hoon Yang

Research output: Contribution to journalArticle

Abstract

There is conflicting evidence for the clinical benefit of statin therapy in patients with vasospastic angina (VSA). We investigated the association of statin therapy with clinical outcomes in relatively large populations with clinically suspected VSA from a nationwide population-based database. Data were collected from the Health Insurance Review and Assessment database records of 4,099 patients that were in an intensive care unit with VSA between January 1, 2008 and May 31, 2015. We divided the patients into a statin group (n = 1,795) and a non-statin group (n = 2,304). The primary outcome was a composite of cardiac arrest and acute myocardial infarction (AMI). The median follow-up duration was 3.8 years (interquartile range: 2.2 to 5.8 years). Cardiac arrest or AMI occurred in 120 patients (5.2%) in the statin group, and 97 patients (5.4%) in the non-statin group (P = 0.976). With inverse probability of treatment weighting, there was no significant difference in the rate of cardiac arrest or AMI between the two groups (adjusted hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.76–1.30; P = 0.937), or even between the non-statin group and high-intensity statin group (adjusted HR, 1.08; 95% CI, 0.69–1.70; P = 0.75). The beneficial association of statin use with the primary outcome was consistently lacking across the various comorbidity types. Statin therapy was not associated with reduced cardiac arrest or AMI in patients with VSA, regardless of statin intensity. Prospective, randomized trials will be needed to confirm our findings.

Original languageEnglish (US)
Article numbere0210498
JournalPLoS One
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Health insurance
health insurance
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Health Insurance
cardiac arrest
myocardial infarction
therapeutics
Heart Arrest
Myocardial Infarction
confidence interval
Therapeutics
Hazards
Databases
Confidence Intervals
Intensive care units
Population
Intensive Care Units
Comorbidity
duration

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Association of statin therapy with clinical outcomes in patients with vasospastic angina : Data from Korean health insurance review and assessment service. / Park, So Jin; Park, Hyejeong; Kang, Danbee; Park, Taek Kyu; Park, Jinkyeong; Cho, Joongbum; Chung, Chi Ryang; Jeon, Kyeongman; Guallar, Eliseo; Cho, Juhee; Suh, Gee Young; Yang, Jeong Hoon.

In: PLoS One, Vol. 14, No. 1, e0210498, 01.01.2019.

Research output: Contribution to journalArticle

Park, So Jin ; Park, Hyejeong ; Kang, Danbee ; Park, Taek Kyu ; Park, Jinkyeong ; Cho, Joongbum ; Chung, Chi Ryang ; Jeon, Kyeongman ; Guallar, Eliseo ; Cho, Juhee ; Suh, Gee Young ; Yang, Jeong Hoon. / Association of statin therapy with clinical outcomes in patients with vasospastic angina : Data from Korean health insurance review and assessment service. In: PLoS One. 2019 ; Vol. 14, No. 1.
@article{021fe7844d14432aac4679546bd0819a,
title = "Association of statin therapy with clinical outcomes in patients with vasospastic angina: Data from Korean health insurance review and assessment service",
abstract = "There is conflicting evidence for the clinical benefit of statin therapy in patients with vasospastic angina (VSA). We investigated the association of statin therapy with clinical outcomes in relatively large populations with clinically suspected VSA from a nationwide population-based database. Data were collected from the Health Insurance Review and Assessment database records of 4,099 patients that were in an intensive care unit with VSA between January 1, 2008 and May 31, 2015. We divided the patients into a statin group (n = 1,795) and a non-statin group (n = 2,304). The primary outcome was a composite of cardiac arrest and acute myocardial infarction (AMI). The median follow-up duration was 3.8 years (interquartile range: 2.2 to 5.8 years). Cardiac arrest or AMI occurred in 120 patients (5.2{\%}) in the statin group, and 97 patients (5.4{\%}) in the non-statin group (P = 0.976). With inverse probability of treatment weighting, there was no significant difference in the rate of cardiac arrest or AMI between the two groups (adjusted hazard ratio [HR], 0.99; 95{\%} confidence interval [CI], 0.76–1.30; P = 0.937), or even between the non-statin group and high-intensity statin group (adjusted HR, 1.08; 95{\%} CI, 0.69–1.70; P = 0.75). The beneficial association of statin use with the primary outcome was consistently lacking across the various comorbidity types. Statin therapy was not associated with reduced cardiac arrest or AMI in patients with VSA, regardless of statin intensity. Prospective, randomized trials will be needed to confirm our findings.",
author = "Park, {So Jin} and Hyejeong Park and Danbee Kang and Park, {Taek Kyu} and Jinkyeong Park and Joongbum Cho and Chung, {Chi Ryang} and Kyeongman Jeon and Eliseo Guallar and Juhee Cho and Suh, {Gee Young} and Yang, {Jeong Hoon}",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0210498",
language = "English (US)",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Association of statin therapy with clinical outcomes in patients with vasospastic angina

T2 - Data from Korean health insurance review and assessment service

AU - Park, So Jin

AU - Park, Hyejeong

AU - Kang, Danbee

AU - Park, Taek Kyu

AU - Park, Jinkyeong

AU - Cho, Joongbum

AU - Chung, Chi Ryang

AU - Jeon, Kyeongman

AU - Guallar, Eliseo

AU - Cho, Juhee

AU - Suh, Gee Young

AU - Yang, Jeong Hoon

PY - 2019/1/1

Y1 - 2019/1/1

N2 - There is conflicting evidence for the clinical benefit of statin therapy in patients with vasospastic angina (VSA). We investigated the association of statin therapy with clinical outcomes in relatively large populations with clinically suspected VSA from a nationwide population-based database. Data were collected from the Health Insurance Review and Assessment database records of 4,099 patients that were in an intensive care unit with VSA between January 1, 2008 and May 31, 2015. We divided the patients into a statin group (n = 1,795) and a non-statin group (n = 2,304). The primary outcome was a composite of cardiac arrest and acute myocardial infarction (AMI). The median follow-up duration was 3.8 years (interquartile range: 2.2 to 5.8 years). Cardiac arrest or AMI occurred in 120 patients (5.2%) in the statin group, and 97 patients (5.4%) in the non-statin group (P = 0.976). With inverse probability of treatment weighting, there was no significant difference in the rate of cardiac arrest or AMI between the two groups (adjusted hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.76–1.30; P = 0.937), or even between the non-statin group and high-intensity statin group (adjusted HR, 1.08; 95% CI, 0.69–1.70; P = 0.75). The beneficial association of statin use with the primary outcome was consistently lacking across the various comorbidity types. Statin therapy was not associated with reduced cardiac arrest or AMI in patients with VSA, regardless of statin intensity. Prospective, randomized trials will be needed to confirm our findings.

AB - There is conflicting evidence for the clinical benefit of statin therapy in patients with vasospastic angina (VSA). We investigated the association of statin therapy with clinical outcomes in relatively large populations with clinically suspected VSA from a nationwide population-based database. Data were collected from the Health Insurance Review and Assessment database records of 4,099 patients that were in an intensive care unit with VSA between January 1, 2008 and May 31, 2015. We divided the patients into a statin group (n = 1,795) and a non-statin group (n = 2,304). The primary outcome was a composite of cardiac arrest and acute myocardial infarction (AMI). The median follow-up duration was 3.8 years (interquartile range: 2.2 to 5.8 years). Cardiac arrest or AMI occurred in 120 patients (5.2%) in the statin group, and 97 patients (5.4%) in the non-statin group (P = 0.976). With inverse probability of treatment weighting, there was no significant difference in the rate of cardiac arrest or AMI between the two groups (adjusted hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.76–1.30; P = 0.937), or even between the non-statin group and high-intensity statin group (adjusted HR, 1.08; 95% CI, 0.69–1.70; P = 0.75). The beneficial association of statin use with the primary outcome was consistently lacking across the various comorbidity types. Statin therapy was not associated with reduced cardiac arrest or AMI in patients with VSA, regardless of statin intensity. Prospective, randomized trials will be needed to confirm our findings.

UR - http://www.scopus.com/inward/record.url?scp=85060804514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060804514&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0210498

DO - 10.1371/journal.pone.0210498

M3 - Article

C2 - 30699150

AN - SCOPUS:85060804514

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0210498

ER -